Skip Nav Destination
Close Modal
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Issue Section
Date
Availability
1-4 of 4
Keywords: FOLFIRINOX
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Journal Articles
Subject Area:
Topic Article Package: ADC (Antibody-Drug Conjugates)
,
Karger e-Journal Backfile Collection 2023
,
Oncology
Julius Roehrle, Stefan Kasper, Jürgen-Walter Treckmann, Peter Markus, Brigitte Schumacher, David Albers, Johanna Wendling, Saskia Ting, Bastian Mende, Marlene Maßmann, Maximilian Markus, Isabel Virchow, Vivian Rosery, Katharina Laue, Gregor Zaun, Karina Kostbade, Michael Pogorzelski, Timm M. Reissig, Sven-Thorsten Liffers, Kurt Schmid, Hans-Ulrich Schildhaus, Martin Schuler, Jens T. Siveke, Marcel Wiesweg
Journal:
Oncology Research and Treatment
Oncol Res Treat (2023) 46 (4): 140–150.
Published Online: 31 January 2023
... are limited. Combination therapy protocols such as FOLFIRINOX and gemcitabine/nab-paclitaxel (Gem/NP) define standard-of-care. Patients may receive a sequence of both regimens as first- and second-line palliative treatment. However, there is no guidance regarding a preferred order. Methods...
Journal Articles
Subject Area:
Oncology
Anke Reinacher-Schick, Dirk Arnold, Marino Venerito, Eray Goekkurt, Anna-Lena Kraeft, Thomas Seufferlein
Journal:
Oncology Research and Treatment
Oncol Res Treat (2022) 45 (12): 752–763.
Published Online: 28 October 2022
..., such as FOLFIRINOX, are important elements in the multidisciplinary management of PDAC. Summary: At least one third of patients with metastatic PDAC are eligible for treatment with FOLFIRINOX. Eligibility criteria include good performance status and the absence of relevant comorbidities. However, chemotherapies can...
Journal Articles
Subject Area:
Oncology
Alexander Queck, Sharra Elango, Christine Koch, Dirk Walter, Jennifer Schmidt, Jonel Trebicka, Jörg Trojan, Ursula Pession, Fabian Finkelmeier, Oliver Waidmann
Journal:
Oncology Research and Treatment
Oncol Res Treat (2022) 45 (3): 79–87.
Published Online: 07 December 2021
... sequence is scarce. After treatment with FOLFIRINOX in first-line, gemcitabine monotherapy was established for years. As a potential treatment alternative after failure of FOLFIRINOX therapy, combination of gemcitabine and nab-paclitaxel is used. However, this combination has formally not yet been approved...
Journal Articles
Subject Area:
Oncology
Journal:
Oncology Research and Treatment
Oncol Res Treat (2021) 44 (9): 476–484.
Published Online: 27 July 2021
...Aditi Kharat; Madeline Brendle; Anindit Chhibber; Nathorn Chaiyakunapruk; Joseph Biskupiak Objectives: FOLFIRINOX, gemcitabine/nab-paclitaxel (gem-nab/P), and gemcitabine-capecitabine (gem-cap) demonstrated superiority over gemcitabine monotherapy for pancreatic cancer (PC). It is still unclear...
